Evidence map›Paper›PMID 36428623›Full record

ArticleCancers2022

Identification of Potential Biomarkers for Cancer Cachexia and Anti-Fn14 Therapy.

Zhipeng Cao, Ingrid J Burvenich, Kening Zhao, Clare Senko, Jason Glab, Renee Fogliaro, Zhanqi Liu, Irvin Jose, Hamsa Puthalakath, Nick J Hoogenraad and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.6field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 6 citations in OpenAlex.

  1. Cancer-Associated Cachexia in the Era of Obesity.International journal of molecular sciences · 2025
    Review
  2. Article
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 2 countries.

Zhipeng CaoDepartment of Biochemistry and Genetics, La Trobe University, Melbourne, VIC 3086, Australia.ORCID 0000-0003-4142-6190
Ingrid J BurvenichTumour Targeting Laboratory, Olivia Newton-John Cancer Research Institute, School of Cancer Medicine, La Trobe University, Melbourne, VIC 3084, Australia.ORCID 0000-0001-8384-2403
Kening ZhaoDepartment of Biochemistry and Genetics, La Trobe University, Melbourne, VIC 3086, Australia.
Clare SenkoTumour Targeting Laboratory, Olivia Newton-John Cancer Research Institute, School of Cancer Medicine, La Trobe University, Melbourne, VIC 3084, Australia.
Jason GlabDepartment of Biochemistry and Genetics, La Trobe University, Melbourne, VIC 3086, Australia.
Renee FogliaroDepartment of Molecular Imaging and Therapy, Austin Health, Heidelberg, VIC 3084, Australia.
Zhanqi LiuTumour Targeting Laboratory, Olivia Newton-John Cancer Research Institute, School of Cancer Medicine, La Trobe University, Melbourne, VIC 3084, Australia.
Irvin JoseDepartment of Biochemistry and Genetics, La Trobe University, Melbourne, VIC 3086, Australia.ORCID 0000-0002-8039-8391
Hamsa PuthalakathDepartment of Biochemistry and Genetics, La Trobe University, Melbourne, VIC 3086, Australia.
Nick J HoogenraadDepartment of Biochemistry and Genetics, La Trobe University, Melbourne, VIC 3086, Australia.
Laura D OsellameDepartment of Biochemistry and Genetics, La Trobe University, Melbourne, VIC 3086, Australia.
Andrew M ScottTumour Targeting Laboratory, Olivia Newton-John Cancer Research Institute, School of Cancer Medicine, La Trobe University, Melbourne, VIC 3084, Australia.
La Trobe University · AUAustin Health · AUThe University of Melbourne · AU

Funding

National Health and Medical Research Council GNT1117541National Health and Medical Research Council GNT1177837Tour de Cure LDOVictorian Cancer Agency Translational Research Grants
6 · The paper itself

Abstract

backgroundDeveloping therapies for cancer cachexia has not been successful to date, in part due to the challenges of achieving robust quantitative measures as a readout of patient treatment. Hence, identifying biomarkers to assess the outcomes of treatments for cancer cachexia is of great interest and important for accelerating future clinical trials.

methodsWe established a novel xenograft model for cancer cachexia with a cachectic human PC3* cell line, which was responsive to anti-Fn14 mAb treatment. Using RNA-seq and secretomic analysis, genes differentially expressed in cachectic and non-cachectic tumors were identified and validated by digital droplet PCR (ddPCR). Correlation analysis was performed to investigate their impact on survival in cancer patients.

resultsA total of 46 genes were highly expressed in cachectic PC3* tumors, which were downregulated by anti-Fn14 mAb treatment. High expression of the top 10 candidates was correlated with low survival and high cachexia risk in different cancer types. Elevated levels of LCN2 were observed in serum samples from cachectic patients compared with non-cachectic cancer patients.

conclusionThe top 10 candidates identified in this study are candidates as potential biomarkers for cancer cachexia. The diagnostic value of LCN2 in detecting cancer cachexia is confirmed in patient samples.

Indexed as

biomarkercancer cachexiaLCN2RNA-seq

Identifiers

PMID36428623
PMCPMC9688504
OpenAlexW4308877626

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.